| | | Sanofi and Baidu ink license agreement for next-gen mRNA therapies and vaccines
Nov. 22, 2021 7:26 AM ET Baidu, Inc. (BIDU), SNY By: Dulan Lokuwithana, SA News Editor
 libre de droit/iStock via Getty Images
Baidu (NASDAQ: BIDU) and Sanofi (NASDAQ: SNY) announced an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign into French pharma giant’s product design pipeline.
Developed in 2020, LinearDesign is an algorithm for mRNA sequence design. Under the partnership, Sanofi ( SNY) will use the platform to optimize mRNA sequences in the development of therapeutics and preventative approaches.
“We have already seen that combining mRNA with computational biology tools makes the process quicker and more effective and has the potential to further transform drug discovery,” remarked Tian Wu, Baidu Corporate Vice President.
The company is honored to team up with Sanofi “to bring life-saving mRNA therapies and vaccines to the global healthcare community," Wu added. |
|
